TY - JOUR
T1 - Biomarkers of Glucose Homeostasis and Inflammation with Risk of Prostate Cancer
T2 - A Case–Cohort Study
AU - Wang, Ying
AU - Gapstur, Susan M.
AU - Newton, Christina C.
AU - McCullough, Marjorie L.
AU - Pollak, Michael N.
AU - Campbell, Peter T.
N1 - Funding Information:
We thank the CPS-II participants and study management group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention’s National Program of Cancer Registries and cancer registries supported by the National Cancer Institute’s Surveillance Epidemiology and End Results Program. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study II (CPS-II) cohort.
Funding Information:
We thank the CPS-II participants and study management group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention?s National Program of Cancer Registries and cancer registries supported by the National Cancer Institute?s Surveillance Epidemiology and End Results Program. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study II (CPS-II) cohort.
Publisher Copyright:
© 2022 American Association for Cancer Research
PY - 2022/4
Y1 - 2022/4
N2 - Background: Few prospective studies have examined biomarkers of glucose homeostasis or inflammation with prostate cancer risk by tumor stage or grade. Methods: We conducted a case–cohort study to examine associations of prediagnosis hemoglobin A1c (HbA1c), C-peptide, and C-reactive protein (CRP) with prostate cancer risk overall and stratified by tumor stage and grade. The study included 390 nonaggressive (T1–2, N0, M0, and Gleason score <8) and 313 aggressive cases (T3–4, or N1, or M1, or Gleason score 8–10) diagnosed after blood draw (1998–2001) and up to 2013, and a random subcohort of 1,303 cancer-free men at blood draw in the Cancer Prevention Study-II Nutrition Cohort. Prentice-weighted Cox proportional hazards regression models were used to estimate HRs and 95% confidence intervals (CI). Results: In the multivariable-adjusted model without body mass index, HbA1c was inversely associated with nonaggressive prostate cancer (HR per unit increase, 0.89; 95% CI, 0.80–1.00; P ¼ 0.04). Analyses stratified by tumor stage and grade separately showed that HbA1c was inversely associated with low-grade prostate cancer (HR per unit increase, 0.89; 95% CI, 0.80–1.00) and positively associated with high-grade prostate cancer (HR per unit increase, 1.15; 95% CI, 1.01–1.30). C-peptide and CRP were not associated with prostate cancer overall or by stage or grade. Conclusions: The current study suggests that associations of hyperglycemia with prostate cancer may differ by tumor grade and stage. Impact: Future studies need to examine prostate cancer by tumor stage and grade, and to better understand the role of hyperglycemia in prostate cancer progression.
AB - Background: Few prospective studies have examined biomarkers of glucose homeostasis or inflammation with prostate cancer risk by tumor stage or grade. Methods: We conducted a case–cohort study to examine associations of prediagnosis hemoglobin A1c (HbA1c), C-peptide, and C-reactive protein (CRP) with prostate cancer risk overall and stratified by tumor stage and grade. The study included 390 nonaggressive (T1–2, N0, M0, and Gleason score <8) and 313 aggressive cases (T3–4, or N1, or M1, or Gleason score 8–10) diagnosed after blood draw (1998–2001) and up to 2013, and a random subcohort of 1,303 cancer-free men at blood draw in the Cancer Prevention Study-II Nutrition Cohort. Prentice-weighted Cox proportional hazards regression models were used to estimate HRs and 95% confidence intervals (CI). Results: In the multivariable-adjusted model without body mass index, HbA1c was inversely associated with nonaggressive prostate cancer (HR per unit increase, 0.89; 95% CI, 0.80–1.00; P ¼ 0.04). Analyses stratified by tumor stage and grade separately showed that HbA1c was inversely associated with low-grade prostate cancer (HR per unit increase, 0.89; 95% CI, 0.80–1.00) and positively associated with high-grade prostate cancer (HR per unit increase, 1.15; 95% CI, 1.01–1.30). C-peptide and CRP were not associated with prostate cancer overall or by stage or grade. Conclusions: The current study suggests that associations of hyperglycemia with prostate cancer may differ by tumor grade and stage. Impact: Future studies need to examine prostate cancer by tumor stage and grade, and to better understand the role of hyperglycemia in prostate cancer progression.
UR - http://www.scopus.com/inward/record.url?scp=85128161473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128161473&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-1060
DO - 10.1158/1055-9965.EPI-21-1060
M3 - Article
C2 - 35149581
AN - SCOPUS:85128161473
VL - 31
SP - 736
EP - 743
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 4
ER -
